Earlier access to palliative care may increase the likelihood that patients with hematologic malignancies nearing end-of-life can die at home.
Receiving care in a community setting is associated with a prolonged maintenance treatment in patients with non-Hodgkin lymphoma.
A recently approved second-line therapy is reasonably effective in the treatment of advanced non-small cell lung cancer, according to a recent real-world study.
A monotherapy produced better overall survival outcomes when compared with a standard combination regimen in patients with heavily pretreated multiple myeloma, according to a recent study.
The US Food and Drug Administration has approved a biosimilar to infliximab for the treatment of rheumatoid arthritis.
The treatment of mantle cell lymphoma carries a significant economic burden in the real-world setting, according to research presented at the ASH Annual Meeting & Exposition.
Patients with soft tissue sarcoma experienced a confirmed clinical response following treatment with a targeted therapy, according to a recent study.
Young patients with head and neck sarcoma treated with proton beam therapy had similar outcomes with less of an impact on quality of life as those treated with traditional photon radiation.
Receipt of treatment for multiple myeloma varies greatly among racial or ethnic minorities.
The adoption of evidence-based surgical practices have influenced treatment patterns for gastric cancer in the United States.